Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Corcept's miricorilant MASLD Phase 1 study completed, University of Missouri siteSep 30Trial updateCorcept Therapeuticsmiricorilant